Healing & Recovery Peptide Research

Gastric-Protective & Tissue-Repair Peptides

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It is one of the most extensively referenced compounds in gut-repair and musculoskeletal-healing literature, with research interest particularly focused on angiogenesis and tendon-healing models.

Cytoskeletal & Cell-Migration Regulation

TB-500 is a synthetic fragment of thymosin beta-4, studied for its role in actin regulation and cell migration — mechanisms relevant to wound-closure research and general tissue-repair literature.

Anti-Inflammatory Fragments

KPV is the minimal active fragment of alpha-MSH(11-13), studied for anti-inflammatory activity that appears independent of the melanocortin receptor's pigmentation effects, with a research base concentrated on cytokine signaling and gut-inflammation models.

Copper-Binding Connective-Tissue Peptides

GHK-Cu is a naturally occurring copper-binding tripeptide studied for its role in skin and connective-tissue research, particularly in models examining collagen synthesis and wound healing.

Combined Blends

KLOW (GHK-Cu, BPC-157, TB-500, and KPV) and the TB-500 + BPC-157 Blend combine multiple repair-focused mechanisms into a single formulation, allowing researchers to study whether complementary pathways — angiogenesis, cell migration, anti-inflammatory activity, and collagen synthesis — produce a compounding effect relative to isolated-peptide protocols. See the full research profiles for KLOW Blend and the TB-500 + BPC-157 Blend.

Nerve & Tissue-Protective Research

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix-B surface of erythropoietin, engineered to selectively activate the "innate repair receptor" (a heteromeric complex of the EPO receptor and CD131) without triggering red-blood-cell production. This receptor is expressed on nerve, glial, and endothelial cells under stress or injury, which has pushed ARA-290's research toward small-fiber nerve regeneration and neuropathic pain — a mechanism distinct from the gastric-, actin-, and copper-based repair pathways above, but conceptually adjacent as tissue-protective, anti-inflammatory research. See its full research profile.

Immune-Modulation Research (Immunity & General Health)

Thymosin Alpha-1 and Vilon both sit apart from the rest of this category: neither is a tissue-repair peptide. Despite sharing a thymic naming lineage with TB-500's parent molecule (thymosin beta-4), Thymosin Alpha-1 is a distinct compound studied for immune-system modulation rather than wound closure or collagen synthesis. Its research base centers on TLR3/4/9 receptor binding and downstream NF-κB/IRF3 signaling, which promotes the maturation and activation of dendritic cells, macrophages, and T-cells. Vilon reaches for the same broad target — immune function in aging — through an entirely different, and more speculative, route: it is the shortest peptide in the Khavinson bioregulator family (the two-amino-acid dipeptide Lys-Glu), proposed to bind DNA in thymic tissue and influence gene expression governing T-cell maturation. Both are relevant to general immune function and health rather than localized tissue repair. See their full research profiles: Thymosin Alpha-1 · Vilon — or the full Thymosin Alpha-1 vs Vilon comparison.

Clinical & Preclinical Trial Data

BPC-157: No completed human clinical trials exist. A registered Phase I trial (42 healthy volunteers) was cancelled in 2016 with no published results, and the only human data available is a small 2025 pilot study of intravenous BPC-157 in 2 healthy adults, reporting no adverse effects. The evidence base is overwhelmingly animal and in-vitro research from Predrag Sikiric's group at the University of Zagreb, covering tendon healing, gut repair, and angiogenesis models. See its full research profile, or how it compares to TB-500.

TB-500: It's important to distinguish TB-500 (the shorter synthetic fragment sold commercially) from full-length Thymosin Beta-4, which is what RegeneRx Biopharmaceuticals actually studied in human trials — the two are related but not identical molecules. RegeneRx's Thymosin Beta-4 trials include: RGN-352 (injectable), a Phase I trial in 40 healthy volunteers that was well tolerated with no adverse events, though a later Phase II cardiovascular trial was placed on a manufacturing-related FDA clinical hold; RGN-137 (topical gel), a Phase II venous stasis ulcer trial showing faster but not statistically significant healing versus placebo; and RGN-259 (ophthalmic), a Phase III trial for neurotrophic keratopathy that met its endpoints for improved healing and comfort. None of this trial data is for TB-500 specifically as sold for research use. See its full research profile.

KPV: No human trials have been conducted. The strongest preclinical evidence comes from Dalmasso et al., who found that oral KPV reduced disease activity and inflammation in mouse models of inflammatory bowel disease, consistent with the anti-inflammatory mechanism first characterized by Catania and Lipton's group. See its full research profile, or its discovery history.

GHK-Cu: Unusually for a research peptide, GHK-Cu has some small-scale human data, though all of it is from topical (not injectable) application. A 21-participant trial found a 28% average increase in skin collagen density after 3 months of daily topical use. A separate 45-participant trial comparing GHK-Cu to a known comparator peptide found modest improvements in wrinkle reduction and skin elasticity that were not statistically significant versus the comparator. No large-scale randomized controlled trials exist. See its full research profile or discovery history, or how it compares to KPV.

ARA-290: Development is further along than most compounds on this page. A Phase 2 randomized, double-blind pilot trial (Dahan et al., Molecular Medicine, 2013; 36 sarcoidosis patients with small-fiber neuropathy) found ARA-290 significantly improved neuropathic pain scores and increased corneal nerve fiber density, a structural marker of nerve regeneration. A follow-up Phase 2b trial (Culver et al., Investigative Ophthalmology & Visual Science, 2017; n=64) replicated the corneal nerve fiber finding and additionally found increased regenerating intraepidermal nerve fibers. A separate 2015 trial in type 2 diabetes patients (4mg/day for 28 days) reported reduced neuropathic symptom scores alongside secondary reductions in HbA1c that persisted through a 56-day observation period. No Phase 3 trial was initiated, and development stalled after the compound's sponsor, Araim Pharmaceuticals, shut down; ARA-290 holds FDA orphan drug status for neuropathic pain in sarcoidosis but has not received full FDA approval.

Thymosin Alpha-1: This is one of the few compounds referenced on this site with a genuinely large, modern randomized trial behind it — and that trial reported a negative result. The ETASS trial (2013, Critical Care; 361 ICU patients with severe sepsis across six Chinese hospitals, 181 on Tα1 versus 180 controls) found a trend toward improved 28-day survival that did not reach statistical significance (p=0.06). The much larger follow-up TESTS trial (2025, The BMJ; 1,106 sepsis patients across 22 Chinese centers, double-blind, placebo-controlled Phase 3) found no significant difference in 28-day mortality (23.4% with Tα1 versus 24.1% with placebo; hazard ratio 0.97, p=0.82). Separately from the sepsis research, synthetic Thymosin Alpha-1 (thymalfasin, brand name Zadaxin) is an approved prescription medicine in more than 35 countries for chronic hepatitis B and C, and holds FDA orphan drug designation for several indications in the United States, though it has not received full FDA approval for any indication.

Vilon: The core evidence is a single, decades-old animal lifespan study (Khavinson & Anisimov, Doklady Biological Sciences): chronic Vilon administration in female CBA mice — a strain predisposed to spontaneous mammary tumors — extended lifespan by 20–40% and reduced the incidence of spontaneous lung adenomas, without significantly changing body weight or food consumption. This has not been independently replicated outside Khavinson-affiliated Russian research, and no human trial of Vilon has been conducted.

See the discovery history behind these peptides →

These compounds are studied for nerve protection and immune-system modulation rather than the direct tissue-repair mechanisms in the catalogue above, which is why they're listed here separately. None are part of our standard inventory, but we can still source them for your order — get in touch for pricing and lead time.